Transcutaneous Bilirubinometers in the Community (TcB RCT)
Jaundice, Neonatal
About this trial
This is an interventional health services research trial for Jaundice, Neonatal focused on measuring Neonatal Jaundice, Physiological Neonatal Jaundice, Neonatal Hyperbilirubinemia, Transcutaneous Bilirubinometer
Eligibility Criteria
Inclusion Criteria:
- All near term (35 and 36 weeks gestational age) and term (37 to 41 weeks) babies living in Alberta Capital Health (CH) region
- Born at any Capital Health or Caritas delivery facility(Royal Alexandra Hospital, Grey Nuns Community Hospital, Misericordia Community Hospital, Sturgeon Community Hospital, Fort Saskatchewan Health Centre, and WestView Health Centre)
- Discharged home from the nursery within 96 hours of life
Exclusion Criteria:
- Babies who do not live in CH region
- Babies born at less than 35 weeks gestational age
- Babies initially admitted to a Special Care Nursery (SCN) or a Neonatal Intensive Care unit (NICU) for more than 72 hours
- Babies born to opting-out mothers will also be excluded
Sites / Locations
- Royal Alexandra Hospital
- Misericordia Community Hospital
- Grey Nuns Community Hospital
- Sturgeon Community Hospital
- Fort Saskatchewan Health Centre
- WestView Health Centre
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
A
B
In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age < 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.